The role of inflammation in progression of breast cancer: Friend or foe? (Review)

International Journal of Oncology

Volumn 47, Issue 3, 2015, Pages 797-805

  Allen, Michael D ^a   Jones, Louise J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Ductal carcinoma in situ; Inflammation; Progression

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; EXEMESTANE; GELATINASE B; INDOLEAMINE 2,3 DIOXYGENASE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB; TRASTUZUMAB; TUMOR MARKER;

B LYMPHOCYTE; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; INFLAMMATION; INTRADUCTAL CARCINOMA; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; BREAST NEOPLASMS; DISEASE COURSE; DRUG EFFECTS; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84938093501     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3075     Document Type: Review

References (90)

1. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, et al: Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102: 627-637, 2010.
2. Price P, Sinnett HD, Gusterson B, Walsh G, A'Hern RP and McKinna JA: Duct carcinoma in situ: Predictors of local recurrence and progression in patients treated by surgery alone. Br J Cancer 61: 869-872, 1990.
3. Welch HG and Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 102: 605-613, 2010.
4. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, et al: Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100: 5974-5979, 2003.
5. Castro NP, Osório CA, Torres C, Bastos EP, Mour?o-Neto M, Soares FA, Brentani HP and Carraro DM: Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 10: R87, 2008.
6. Moelans CB, de Weger RA, Monsuur HN, Maes AH and van Diest PJ: Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: A multiplex ligationdependent probe amplification study. Anal Cell Pathol (Amst) 33: 165-173, 2010.
7. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, et al: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105: 701-710, 2013.
8. Allen M and Jones LJ: Jekyll and Hyde: The role of the microenvironment on the progression of cancer. J Pathol 223: 162-176, 2011.
9. Bissell MJ, Hall HG and Parry G: How does the extracellular matrix direct gene expression? J Theor Biol 99: 31-68, 1982.
10. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E and Syrjänen K: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28A: 859-864, 1992.
11. Stewart T, Tsai SC, Grayson H, Henderson R and Opelz G: Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346: 796-798, 1995.
12. Lee AH, Happerfield LC, Bobrow LG and Millis RR: Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol 181: 200-206, 1997.
13. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN and Pollard JW: Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66: 11238-11246, 2006.
14. Lee AH, Dublin EA and Bobrow LG: Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. J Pathol 187: 285-290, 1999.
15. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J and Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625-4629, 1996.
16. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol 26: 259-271, 2015.
17. Biswas SK and Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11: 889-896, 2010.
18. Tang X: Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett 332: 3-10, 2013.
19. Bögels M, Braster R, Nijland PG, Gül N, van de Luijtgaarden W, Fijneman RJ, Meijer GA, Jimenez CR, Beelen RH and van Egmond M: Carcinoma origin dictates differential skewing of monocyte function. OncoImmunology 1: 798-809, 2012.
20. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC and Balkwill FR: ?Re-educating? tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205: 1261-1268, 2008.
21. Coussens LM and Pollard JW: Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol 3: 3, 2011.
22. Guy CT, Cardiff RD and Muller WJ: Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961, 1992.
23. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillart P and Lidereau R: Anticolony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86: 120-126, 1994.
24. Lin EY, Nguyen AV, Russell RG and Pollard JW: Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727-740, 2001.
25. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67, 2011.
26. Soria G and Ben-Baruch A: The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267: 271-285, 2008.
27. Murdoch C, Giannoudis A and Lewis CE: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104: 2224-2234, 2004.
28. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G: Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9: R15, 2007.
29. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H and Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6: 3282-3289, 2000.
30. Goede V, Brogelli L, Ziche M and Augustin HG: Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 82: 765-770, 1999.
31. Valković T, Lucin K, Krstulja M, Dobi-Babić R and Jonjić N: Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194: 335-340, 1998.
32. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T and Kerin MJ: Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 13: 5020-5027, 2007.
33. Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E and Koelbl H: Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 25: 14-17, 2004.
34. Lyon DE, McCain NL, Walter J and Schubert C: Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57: 51-58, 2008.
35. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225, 2011.
36. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I and Ben-Baruch A: Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59: 4681-4687, 1999.
37. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y and Abe A: Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7: 285-289, 2001.
38. Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I and Ben-Baruch A: The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12: 4474-4480, 2006.
39. Stormes KA, Lemken CA, Lepre JV, Marinucci MN and Kurt RA: Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat 89: 209-212, 2005.
40. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE and Balkwill FR: A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63: 8360-8365, 2003.
41. Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP and Pestell RG: CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 72: 3839-3850, 2012.
42. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007.
43. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, et al: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107: 2112-2122, 2006.
44. Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, Blades J, Li JL, Allen P, Leek R, et al: Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol 176: 2019-2028, 2010.
45. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H and Era S: Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncol Rep 14: 425-431, 2005.
46. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO and Green AR: Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65: 159-163, 2012.
47. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al: Expression of interleukin-1beta in human breast carcinoma. Cancer 80: 421-434, 1997.
48. Slaney CY, Rautela J and Parker BS: The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res 73: 5852-5857, 2013.
49. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, et al: Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18: 1224-1231, 2012.
50. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, et al: Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13: 23-35, 2008.
51. Melani C, Sangaletti S, Barazzetta FM, Werb Z and Colombo MP: Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 67: 11438-11446, 2007.
52. Zhang Y, Lv D, Kim HJ, Kurt RA, Bu W, Li Y and Ma X: A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res 23: 394-408, 2013.
53. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ and Montero AJ: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49-59, 2009.
54. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J and Ren X: Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190: 3783-3797, 2013.
55. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L and Raus J: Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 12: 1463-1466, 1992.
56. Watanabe MA, Oda JM, Amarante MK and Cesar Voltarelli J: Regulatory T cells and breast cancer: Implications for immunopathogenesis. Cancer Metastasis Rev 29: 569-579, 2010.
57. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S and Lee PP: Profile of immune cells in axillary lymph nodes predicts diseasefree survival in breast cancer. PLoS Med 2: e284, 2005.
58. Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336, 2003.
59. Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, Dagna-Bricarelli F, Sartirana C, Matthes-Martin S, Lawitschka A, et al: Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 116: 1713-1722, 2006.
60. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD and Rudensky AY: Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 103: 6659-6664, 2006.
61. Li B, Saouaf SJ, Samanta A, Shen Y, Hancock WW and Greene MI: Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Curr Opin Immunol 19: 583-588, 2007.
62. Gupta S, Joshi K, Wig JD and Arora SK: Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol 46: 792-797, 2007.
63. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL and Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380, 2006.
64. Liu Y and Zheng P: FOXP3 and breast cancer: Implications for therapy and diagnosis. Pharmacogenomics 8: 1485-1487, 2007.
65. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29: 1949-1955, 2011.
66. Wernicke M: Quantitative morphologic assessment of immunoreactivity in regional lymph nodes of patients with carcinoma of the breast. Surg Gynecol Obstet 140: 919-924, 1975.
67. Urdiales-Viedma M, Nogales-Fernandez F, Martos-Padilla S and Sanchez-Cantalejo E: Breast tumors: Immunoglobulins in axillary lymph nodes. Tumori 72: 575-579, 1986.
68. Tan EM and Shi FD: Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol 134: 169-177, 2003.
69. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO and Green AR: The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132: 545-553, 2012.
70. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kölbl H and Gehrmann M: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413, 2008.
71. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N and Coussens LM: CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91-102, 2009.
72. van der Most RG, Currie AJ, Robinson BW and Lake RA: Decoding dangerous death: How cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ 15: 13-20, 2008.
73. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A and Kroemer G: The anticancer immune response: Indispensable for therapeutic success? J Clin Invest 118: 1991-2001, 2008.
74. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L and Smyth MJ: Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 71: 4809-4820, 2011.
75. Criscitiello C and Curigliano G: Immunotherapeutics for breast cancer. Curr Opin Oncol 25: 602-608, 2013.
76. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-1796, 2008.
77. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32: 2959-2966, 2014.
78. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31: 860-867, 2013.
79. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 25: 1544-1550, 2014.
80. Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, et al: Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol 33: 701-708, 2015.
81. Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T and Dermime S: FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 8: 57, 2008.
82. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D and Gillanders WE: The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139: 667-676, 2013.
83. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571, 2014.
84. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558-562, 2014.
85. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.
86. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
87. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
88. Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, et al: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 16: 3485-3494, 2010.
89. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW and Smyth MJ: Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 108: 7142-7147, 2011.
90. Hünig T: The storm has cleared: Lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 12: 317-318, 2012.